Vericel (VCEL) to Release Earnings on Thursday

Vericel (NASDAQ:VCEL) is projected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Vericel to post earnings of $0.31 per share and revenue of $76.47 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Vericel Trading Up 0.4 %

Shares of NASDAQ VCEL opened at $52.52 on Wednesday. Vericel has a twelve month low of $39.12 and a twelve month high of $63.00. The stock has a fifty day simple moving average of $57.48 and a 200-day simple moving average of $51.75. The stock has a market capitalization of $2.59 billion, a PE ratio of 875.48 and a beta of 1.72.

Insiders Place Their Bets

In other Vericel news, insider Jonathan Siegal sold 1,092 shares of Vericel stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total transaction of $67,693.08. Following the completion of the sale, the insider now directly owns 1,206 shares of the company’s stock, valued at $74,759.94. The trade was a 47.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jonathan Mark Hopper sold 10,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $58.72, for a total value of $587,200.00. Following the completion of the sale, the insider now directly owns 58,371 shares of the company’s stock, valued at $3,427,545.12. The trade was a 14.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 20,100 shares of company stock valued at $1,206,072 in the last ninety days. Insiders own 5.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on VCEL. Truist Financial boosted their target price on Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Canaccord Genuity Group boosted their target price on Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Stephens reissued an “overweight” rating and set a $65.00 target price on shares of Vericel in a research note on Wednesday, January 15th. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Vericel in a research note on Wednesday, January 15th. Finally, BTIG Research boosted their target price on Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $63.14.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.